Cite

HARVARD Citation

    Ma, S. et al. (2021). Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. Oncoimmunology. p. . [Online]. 
  
Back to record